Arcturus Therapeutics (ARCT) said Friday the European Commission granted marketing authorization for Kostaive, a self-amplifying mRNA COVID-19 vaccine for individuals aged 18 and above.
The biotechnology company said Kostaive is the first self-amplifying mRNA COVID vaccine to receive European Commission clearance and is currently marketed in Japan against the disease.
Kostaive showed "superior" immunogenicity and maintained antibody levels for up to 12 months post-vaccination compared to traditional mRNA vaccines, the company said.
The company also said that the approval follows a favorable opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency on Dec. 12 and is valid across all European countries.
The company's shares were up 2.1% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。